Catalog No.: PC-60618Not For Human Use, Lab Use Only.
AZD 5069 (AZD5069) is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1.
AZD 5069 (AZD5069) is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1.
AZD5069 weakly inhibits CXCL8 binding to CXCR1 with pIC50<7, and no affinity for CCR2 and CCR5.
AZD5069 inhibits neutrophil chemotaxis with pA2 of 9.6, and adhesion molecule expression of 6.9, in response to CXCL1.
AZD5069 demonstrates potential activity in acute LPS-induced lung inflammation models.
